Regenxbio
RGNX
170 hedge funds and large institutions have $939M invested in Regenxbio in 2020 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 52 increasing their positions, 63 reducing their positions, and 36 closing their positions.
3.5% less ownership
Funds ownership: 81.5% → 78% (-3.5%)
9% less funds holding
Funds holding: 187 → 170 (-17)
15% less call options, than puts
Call options by funds: $5.93M | Put options by funds: $6.95M
17% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 63
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
24% less capital invested
Capital invested by funds: $1.23B → $939M (-$292M)
39% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
+$10.8M |
| 2 |
O
OrbiMed
New York
|
+$10M |
| 3 |
Goldman Sachs
New York
|
+$8.27M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$6.44M |
| 5 |
JP Morgan Chase
New York
|
+$5.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$12.4M |
| 2 |
BlackRock
New York
|
-$8.09M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$7.08M |
| 4 |
CG
Carmignac Gestion
Paris,
France
|
-$5.02M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$4.59M |
RGNX Hedge Fund Activity: Q1 2020 in Review
170 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q1 2020, worth a combined $939M — down 24% from $1.23B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of RGNX and 22 opened new positions — a net loss of 14 holders — while 63 trimmed existing stakes and 52 added.
The largest buyer was Marshall Wace North America, opening a new position worth an estimated $10.8M. The largest seller was Franklin Resources, exiting entirely with an estimated $12.4M sold.
- 170 institutional investors held Regenxbio (RGNX) as of Q1 2020, down from 187 in Q4 2019.
- Funds reported $939M of Regenxbio stock for Q1 2020, down 24% quarter-over-quarter.
- 22 funds opened new Regenxbio positions in Q1 2020 and 36 closed out, a net change of -14 holders.
- The largest Regenxbio buyer in Q1 2020 was Marshall Wace North America, an estimated $10.8M added.
- The largest Regenxbio seller in Q1 2020 was Franklin Resources, an estimated $12.4M sold.
Based on aggregated 13F filings for Q1 2020.